Naglazyme® for MPS VI
Current Clinical Trials: MPS VI
Indication: Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)
Investigational Therapeutic: Naglazyme
Study Type: Phase 4
Goal: The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.
Status: This study is currently recruiting participants
Additional information: View on Clinicaltrials.gov